Intelligence Report · ~12 min read
Alnylam Pharmaceuticals Intelligence Report
Generated from 2 signals · 2 evidence sources
Type
Company Intelligence ReportGenerated
Aug 5, 2026
Confidence
Moderate Confidence · 73%
Evidence
11 items
Sources
8
Executive Summary
Synthesized assessment from linked signals, findings, and evidence relationships.
Alnylam Pharmaceuticals maintains an active intelligence profile across Metabolic Disorders, Obesity, Oncology, Hepatocellular Carcinoma. 2 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 73% across 2 tracked sources. Highest-priority development: FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma. Regulatory precedent. Why this matters: provides agency context on approval that may shape timing or evidence expectations for Alnylam Pharmaceuticals.
Key Developments
Material intelligence events ranked by strategic relevance.
- regulatory
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Regulatory precedent may inform portfolio positioning
View detail - regulatory
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer
Regulatory precedent may inform portfolio positioning
View detail - regulatory
FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer
Regulatory precedent may inform portfolio positioning
View detail - regulatory
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers
Regulatory precedent may inform portfolio positioning
View detail - regulatory
October - December 2024 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
Regulatory precedent may inform portfolio positioning
View detail - regulatory
S6 (R1) Addendum: Preclinical Safety Evaluation of Biotechnology - Derived Pharmaceuticals
Regulatory precedent may inform portfolio positioning
View detail - regulatory
New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
Regulatory precedent may inform portfolio positioning
View detail - regulatory
Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
Regulatory precedent may inform portfolio positioning
View detail - regulatory
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Regulatory precedent may inform portfolio positioning
View detail
Strategic Implications
Portfolio and competitive decisions informed by this intelligence profile.
Opportunity score 44 with buyer quality 6 (Emerging). Competitive pressure: Low. Portfolio impact: High.
Supporting Evidence
Evidence-backed items with source attribution and confidence disclosure.
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Moderate Confidence · 65%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceFDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer
Moderate Confidence · 65%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceFDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer
Moderate Confidence · 83%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceS9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers
Moderate Confidence · 83%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceOctober - December 2024 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
Moderate Confidence · 72%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceS6 (R1) Addendum: Preclinical Safety Evaluation of Biotechnology - Derived Pharmaceuticals
Moderate Confidence · 72%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceNew Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
Moderate Confidence · 72%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceJanus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
Moderate Confidence · 72%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceFDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Moderate Confidence · 72%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.
Signals
- Alnylam's ALN-2232 Undergoing Evaluation for Obesity Treatment
Metabolic Disorders · Obesity
- Alnylam's ALN-BCAT Study in Hepatocellular Carcinoma Evaluates Safety and Efficacy
Oncology · Hepatocellular Carcinoma